Complementary and alternative medicine in men's health

Journal of Men's Health

Volumn 5, Issue 4, 2008, Pages 305-313

  Park, Jinsung ^a   Shin, Dong Wook ^b   Ahn, Tai Young ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

Author keywords

Benign prostatic hyperplasia; Complementary and alternative medicine; Erectile dysfunction; Prostate cancer

Indexed keywords

ALPHA TOCOPHEROL; ARGININE; AZUPROSTAT; CAMPESTEROL; CERNITIN; DAIDZEIN; DOCETAXEL; FATTY ACID; FINASTERIDE; GANODERMA LUCIDUM EXTRACT; GARLIC EXTRACT; GENISTEIN; ISOFLAVONE; ISOFLAVONOID; LAURIC ACID; LIGNAN DERIVATIVE; LUPEOL; LYCOPENE; PHYTOESTROGEN; PHYTOSTEROL; POLYSACCHARIDE; PYGEUM AFRICANUM EXTRACT; SABAL EXTRACT; SELENIUM; SITOSTEROL; STEROL DERIVATIVE; STIGMASTEROL; TAMSULOSIN; TERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D; YOHIMBINE;

ALTERNATIVE MEDICINE; CLINICAL TRIAL; DIET THERAPY; HUMAN; MEDICAL SPECIALIST; MEN'S HEALTH; METHODOLOGY; NONHUMAN; PHYTOTHERAPY; PINE; PREMATURE EJACULATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SABAL; SAMPLE SIZE; SEXUAL DYSFUNCTION; SPRUCE; WELLBEING;

EID: 56949101179     PISSN: 18756867     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jomh.2008.08.004     Document Type: Review

References (100)

1. Eisenberg D.M., Kessler R.C., Foster C., Norlock F.E., Calkins D.R., and Delbanco T.L. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. N Engl J Med 328 (1993) 246-252
2. Lagiou P., Wuu J., Trichopoulou A., Hsieh C.C., Adami H.O., and Trichopoulos D. Diet and benign prostatic hyperplasia: a study in Greece. Urology 54 (1999) 284-290
3. Bravi F., Bosetti C., Dal Maso L., Talamini R., Montella M., Negri E., et al. Macronutrients, fatty acids, cholesterol, and risk of benign prostatic hyperplasia. Urology 67 (2006) 1205-1211
4. Bravi F., Bosetti C., Dal Maso L., Talamini R., Montella M., Negri E., et al. Food groups and risk of benign prostatic hyperplasia. Urology 67 (2006) 73-79
5. Suzuki S., Platz E.A., Kawachi I., Willett W.C., and Giovannucci E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 75 (2002) 689-697
6. Moyad M.A. Dietary fat reduction to reduce prostate cancer risk: controlled enthusiasm, learning a lesson from breast or other cancers, and the big picture. Urology 59 (2002) 51-62
7. De Marzo A.M., Coffey D.S., and Nelson W.G. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 53 (1999) 29-39 discussion 42
8. Evans B.A., Griffiths K., and Morton M.S. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147 (1995) 295-302
9. Chen L., Stacewicz-Sapuntzakis M., Duncan C., Sharifi R., Ghosh L., van Breemen R., et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst 93 (2001) 1872-1879
10. Block G., Patterson B., and Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18 (1992) 1-29
11. Devrim E., and Durak I. Is garlic a promising food for benign prostatic hyperplasia and prostate cancer?. Mol Nutr Food Res 51 (2007) 1319-1323
12. Lowe F.C., and Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology 53 (1999) 671-678
13. Buck A.C. Phytotherapy for the prostate. Br J Urol 78 (1996) 325-336
14. Lowe F.C., and Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 48 (1996) 12-20
15. Dreikorn K. Complementary and alternative medicine in urology. BJU Int 96 (2005) 1177-1184
16. Dedhia R.C., and McVary K.T. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 179 (2008) 2119-2125
17. Fong Y.K., Milani S., and Djavan B. Role of phytotherapy in men with lower urinary tract symptoms. Curr Opin Urol 15 (2005) 45-48
18. Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., and Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: asystematic review. JAMA 280 (1998) 1604-1609
19. Boyle P., Robertson C., Lowe F., and Roehrborn C. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 93 (2004) 751-756
20. Bent S., Kane C., Shinohara K., Neuhaus J., Hudes E.S., Goldberg H., et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 354 (2006) 557-566
21. Zlotta A.R., Teillac P., Raynaud J.P., and Schulman C.C. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (permixon), tamsulosin or finasteride. Eur Urol 48 (2005) 269-276
22. Breza J., Dzurny O., Borowka A., Hanus T., Petrik R., Blane G., et al. Efficacy and acceptability of tadenan (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multicentre trial in central Europe. Curr Med Res Opin 14 (1998) 127-139
23. Chatelain C., Autet W., and Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology 54 (1999) 473-478
24. Ishani A., MacDonald R., Nelson D., Rutks I., and Wilt T.J. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med 109 (2000) 654-664
25. Melo E.A., Bertero E.B., Rios L.A., and Mattos Jr. D. Evaluating the efficiency of a combination of Pygeum africanum and stinging nettle (Urtica dioica) extracts in treating benign prostatic hyperplasia (BPH): double-blind, randomized, placebo controlled trial. Int Braz J Urol 28 (2002) 418-425
26. Berges R.R., Kassen A., and Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int 85 (2000) 842-846
27. Berges R.R., Windeler J., Trampisch H.J., and Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet 345 (1995) 1529-1532
28. Klippel K.F., Hiltl D.M., and Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study Group. Br J Urol 80 (1997) 427-432
29. MacDonald R., Ishani A., Rutks I., and Wilt T.J. A systematic review of cernilton for the treatment of benign prostatic hyperplasia. BJU Int 85 (2000) 836-841
30. Fujita R., Liu J., Shimizu K., Konishi F., Noda K., Kumamoto S., et al. Anti-androgenic activities of Ganoderma lucidum. J Ethnopharmacol 102 (2005) 107-112
31. Shibata Y., Kashiwagi B., Arai S., Fukabori Y., and Suzuki K. Administration of extract of mushroom Phellinus linteus induces prostate enlargement with increase in stromal component in experimentally developed rat model of benign prostatic hyperplasia. Urology 66 (2005) 455-460
32. Chan J.M., Elkin E.P., Silva S.J., Broering J.M., Latini D.M., and Carroll P.R. Total and specific complementary and alternative medicine use in a large cohort of men with prostate cancer. Urology 66 (2005) 1223-1228
33. Eng J., Ramsum D., Verhoef M., Guns E., Davison J., and Gallagher R. A population-based survey of complementary and alternative medicine use in men recently diagnosed with prostate cancer. Integr Cancer Ther 2 (2003) 212-216
34. Lippert M.C., McClain R., Boyd J.C., and Theodorescu D. Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86 (1999) 2642-2648
35. Nam R.K., Fleshner N., Rakovitch E., Klotz L., Trachtenberg J., Choo R., et al. Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 161 (1999) 1521-1524
36. Giovannucci E., Ascherio A., Rimm E.B., Stampfer M.J., Colditz G.A., and Willett W.C. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 87 (1995) 1767-1776
37. Di Mascio P., Kaiser S., and Sies H. Lycopene as the most efficient biological carotenoid singlet oxygen quencher. Arch Biochem Biophys 274 (1989) 532-538
38. Tang L., Jin T., Zeng X., and Wang J.S. Lycopene inhibits the growth of human androgen-independent prostate cancer cells in vitro and in balb/c nude mice. J Nutr 135 (2005) 287-290
39. Matlaga B.R., Hall M.C., Stindt D., and Torti F.M. Response of hormone refractory prostate cancer to lycopene. J Urol 166 (2001) 613
40. Kucuk O., Sarkar F.H., Sakr W., Djuric Z., Pollak M.N., Khachik F., et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev 10 (2001) 861-868
41. Ansari M.S., and Gupta N.P. A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92 (2003) 375-378 discussion 8
42. Clark P.E., Hall M.C., Borden Jr. L.S., Miller A.A., Hu J.J., Lee W.R., et al. Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67 (2006) 1257-1261
43. Ansari M.S., and Gupta N.P. Lycopene: a novel drug therapy in hormone refractory metastatic prostate cancer. Urol Oncol 22 (2004) 415-420
44. Kirsh V.A., Mayne S.T., Peters U., Chatterjee N., Leitzmann M.F., Dixon L.B., et al. A prospective study of lycopene and tomato product intake and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 92-98
45. Bunker C.H., McDonald A.C., Evans R.W., de la Rosa N., Boumosleh J.M., and Patrick A.L. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer 57 (2007) 130-137
46. Campbell M.J., and Koeffler H.P. Toward therapeutic intervention of cancer by vitamin D compounds. J Natl Cancer Inst 89 (1997) 182-185
47. Hanchette C.L., and Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 70 (1992) 2861-2869
48. Corder E.H., Guess H.A., Hulka B.S., Friedman G.D., Sadler M., Vollmer R.T., et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev 2 (1993) 467-472
49. Schwartz G.G. Vitamin D and the epidemiology of prostate cancer. Semin Dial 18 (2005) 276-289
50. John E.M., Koo J., and Schwartz G.G. Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. Cancer Epidemiol Biomarkers Prev 16 (2007) 1283-1286
51. Liu G., Oettel K., Ripple G., Staab M.J., Horvath D., Alberti D., et al. Phase I trial of 1alpha-hydroxyvitamin D(2) in patients with hormone refractory prostate cancer. Clin Cancer Res 8 (2002) 2820-2827
52. Liu G., Wilding G., Staab M.J., Horvath D., Miller K., Dresen A., et al. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin Cancer Res 9 (2003) 4077-4083
53. Schwartz G.G., Hall M.C., Stindt D., Patton S., Lovato J., and Torti F.M. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 11 (2005) 8680-8685
54. Beer T.M., Eilers K.M., Garzotto M., Egorin M.J., Lowe B.A., and Henner W.D. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 21 (2003) 123-128
55. Beer T.M., Ryan C.W., Venner P.M., Petrylak D.P., Chatta G.S., Ruether J.D., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ascent investigators. J Clin Oncol 25 (2007) 669-674
56. Lim H.S., Roychoudhuri R., Peto J., Schwartz G., Baade P., and Moller H. Cancer survival is dependent on season of diagnosis and sunlight exposure. Int J Cancer 119 (2006) 1530-1536
57. Webber M.M., Perez-Ripoll E.A., and James G.T. Inhibitory effects of selenium on the growth of du-145 human prostate carcinoma cells in vitro. Biochem Biophys Res Commun 130 (1985) 603-609
58. Jiang C., Wang Z., Ganther H., and Lu J. Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of du-145 prostate cancer cells. Cancer Res 61 (2001) 3062-3070
59. Clark L.C., Combs Jr. G.F., Turnbull B.W., Slate E.H., Chalker D.K., Chow J., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276 (1996) 1957-1963
60. Combs Jr. G.F., Clark L.C., and Turnbull B.W. An analysis of cancer prevention by selenium. Biofactors 14 (2001) 153-159
61. Combs Jr. G.F. Status of selenium in prostate cancer prevention. Br J Cancer 91 (2004) 195-199
62. Gunawardena K., Murray D.K., and Meikle A.W. Vitamin E and other antioxidants inhibit human prostate cancer cells through apoptosis. Prostate 44 (2000) 287-295
63. Israel K., Yu W., Sanders B.G., and Kline K. Vitamin E succinate induces apoptosis in human prostate cancer cells: role for Fas in vitamin E succinate-triggered apoptosis. Nutr Cancer 36 (2000) 90-100
64. Heinonen O.P., Albanes D., Virtamo J., Taylor P.R., Huttunen J.K., Hartman A.M., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 90 (1998) 440-446
65. Chan J.M., Stampfer M.J., Ma J., Rimm E.B., Willett W.C., and Giovannucci E.L. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the united states. Cancer Epidemiol Biomarkers Prev 8 (1999) 893-899
66. Klein E.A., Thompson I.M., Lippman S.M., Goodman P.J., Albanes D., Taylor P.R., et al. Select: the next prostate cancer prevention trial. Selenum and Vitamin E Cancer Prevention Trial. J Urol 166 (2001) 1311-1315
67. Gupta S., Hastak K., Ahmad N., Lewin J.S., and Mukhtar H. Inhibition of prostate carcinogenesis in tramp mice by oral infusion of green tea polyphenols. Proc Natl Acad Sci USA 98 (2001) 10350-10355
68. Bettuzzi S., Brausi M., Rizzi F., Castagnetti G., Peracchia G., and Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 66 (2006) 1234-1240
69. Brausi M., Rizzi F., and Bettuzzi S. Chemoprevention of human prostate cancer by green tea catechins: two years later. A follow-up update. Eur Urol 54 2 (2008) 472-473
70. Jacobsen B.K., Knutsen S.F., and Fraser G.E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control 9 (1998) 553-557
71. Mentor-Marcel R., Lamartiniere C.A., Eltoum I.E., Greenberg N.M., and Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 61 (2001) 6777-6782
72. Kumar N.B., Cantor A., Allen K., Riccardi D., Besterman-Dahan K., Seigne J., et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate 59 (2004) 141-147
73. Pendleton J.M., Tan W.W., Anai S., Chang M., Hou W., Shiverick K.T., et al. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer 8 (2008) 132
74. Pienta K.J., Naik H., Akhtar A., Yamazaki K., Replogle T.S., Lehr J., et al. Inhibition of spontaneous metastasis in a rat prostate cancer model by oral administration of modified citrus pectin. J Natl Cancer Inst 87 (1995) 348-353
75. Guess B.W., Scholz M.C., Strum S.B., Lam R.Y., Johnson H.J., and Jennrich R.I. Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study. Prostate Cancer Prostatic Dis 6 (2003) 301-304
76. DiPaola R.S., Zhang H., Lambert G.H., Meeker R., Licitra E., Rafi M.M., et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 339 (1998) 785-791
77. de la Taille A., Hayek O.R., Burchardt M., Burchardt T., and Katz A.E. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Altern Complement Med 6 (2000) 449-451
78. Small E.J., Frohlich M.W., Bok R., Shinohara K., Grossfeld G., Rozenblat Z., et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 18 (2000) 3595-3603
79. Oh W.K., Kantoff P.W., Weinberg V., Jones G., Rini B.I., Derynck M.K., et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 22 (2004) 3705-3712
80. Miller D.R., Anderson G.T., Stark J.J., Granick J.L., and Richardson D. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 16 (1998) 3649-3655
81. Zi X., and Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via g1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proc Natl Acad Sci USA 96 (1999) 7490-7495
82. Singh R.P., Deep G., Blouin M.J., Pollak M.N., and Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma pc-3 tumor xenograft. Carcinogenesis 28 (2007) 2567-2574
83. Agarwal C., Singh R.P., and Agarwal R. Grape seed extract induces apoptotic death of human prostate carcinoma DU145 cells via caspases activation accompanied by dissipation of mitochondrial membrane potential and cytochrome c release. Carcinogenesis 23 (2002) 1869-1876
84. Moody J.A., Vernet D., Laidlaw S., Rajfer J., and Gonzalez-Cadavid N.F. Effects of long-term oral administration of L-arginine on the rat erectile response. J Urol 158 (1997) 942-947
85. Gur S., Kadowitz P.J., Trost L., and Hellstrom W.J. Optimizing nitric oxide production by time dependent L-arginine administration in isolated human corpus cavernosum. J Urol 178 (2007) 1543-1548
86. Chen J., Wollman Y., Chernichovsky T., Iaina A., Sofer M., and Matzkin H. Effect of oral administration of high-dose nitric oxide donor L-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study. BJU Int 83 (1999) 269-273
87. Klotz T., Mathers M.J., Braun M., Bloch W., and Engelmann U. Effectiveness of oral L-arginine in first-line treatment of erectile dysfunction in a controlled crossover study. Urol Int 63 (1999) 220-223
88. Lebret T., Herve J.M., Gorny P., Worcel M., and Botto H. Efficacy and safety of a novel combination of L-arginine glutamate and yohimbine hydrochloride: a new oral therapy for erectile dysfunction. Eur Urol 41 (2002) 608-613 discussion 13
89. Kernohan A.F., McIntyre M., Hughes D.M., Tam S.W., Worcel M., and Reid J.L. An oral yohimbine/L-arginine combination (NMI 861) for the treatment of male erectile dysfunction: a pharmacokinetic, pharmacodynamic and interaction study with intravenous nitroglycerine in healthy male subjects. Br J Clin Pharmacol 59 (2005) 85-93
90. Stanislavov R., and Nikolova V. Treatment of erectile dysfunction with pycnogenol and L-arginine. J Sex Marital Ther 29 (2003) 207-213
91. Hong B., Ji Y.H., Hong J.H., Nam K.Y., and Ahn T.Y. A double-blind crossover study evaluating the efficacy of Korean red ginseng in patients with erectile dysfunction: a preliminary report. J Urol 168 (2002) 2070-2073
92. Price A., and Gazewood J. Korean red ginseng effective for treatment of erectile dysfunction. J Fam Pract 52 (2003) 20-21
93. Conaglen H.M., Suttie J.M., and Conaglen J.V. Effect of deer velvet on sexual function in men and their partners: a double-blind, placebo-controlled study. Arch Sex Behav 32 (2003) 271-278
94. Cohen A.J., and Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 24 (1998) 139-143
95. Kang B.J., Lee S.J., Kim M.D., and Cho M.J. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 17 (2002) 279-284
96. Cui Y., Feng Y., Chen L., Zhou Y., Yang X.Q., He J., et al. Randomized and controlled research of Chinese drug acupoint injection therapy for erectile dysfunction. Zhongguo Zhen Jiu 27 (2007) 881-885 [In Chinese]
97. Yaman L.S., Kilic S., Sarica K., Bayar M., and Saygin B. The place of acupuncture in the management of psychogenic impotence. Eur Urol 26 (1994) 52-55
98. Aydin S., Ercan M., Caskurlu T., Tasci A.I., Karaman I., Odabas O., et al. Acupuncture and hypnotic suggestions in the treatment of non-organic male sexual dysfunction. Scand J Urol Nephrol 31 (1997) 271-274
99. Engelhardt P.F., Daha L.K., Zils T., Simak R., Konig K., and Pfluger H. Acupuncture in the treatment of psychogenic erectile dysfunction: first results of a prospective randomized placebo-controlled study. Int J Impot Res 15 (2003) 343-346
100. Dhikav V., Karmarkar G., Gupta M., and Anand K.S. Yoga in premature ejaculation: a comparative trial with fluoxetine. J Sex Med 4 (2007) 1726-1732